| 注册
期刊信息/Journal information
Pharmacoeconomics and Policy

:西安交通大学

:季刊

:2950-2667

:pandp@mail.xjtu.edu.cn;ppeditor@xjtu.edu.cn

:712046

:陕西省西安市长安区高桥街道西安交通大学

Pharmacoeconomics and Policy/Journal 药物经济与政策(英文)
《药物经济与政策(英文)》(Pharmacoeconomics and Policy)(季刊),由西安交通大学主办。期刊聚焦国内外药物经济学、卫生技术评估、人工智能等颠覆性技术驱动的创新医疗技术和药械...展开全部>>
正式出版
收录年份
    2026年02期Issue 02,2026

    Temporal trends and hierarchical disparities of antibiotic utilization patterns:A longitudinal analysis in Shanghai,20172024

    Rui Huang;Biao Wang;Qianqian Yu;Qingwei Tang;Junyu Niu;Li Luo;P.100-109

    Comparative review of selected health technology assessment agencies:Features and insights for health technology assessment development and improvement

    Zonglin Dai;Effie Ka Yue Cheung;Ting Wang;David Makram Bishaie;Lei Si;Benjamin Hon Kei Yip;Yingyao Chen;Ian Chi Kei Wong;Andrew J.Mirelman;Manuel Antonio Espinoza;Xue Li;P.60-68

    Cost-effectiveness analysis of multiple fall prevention interventions for older adults in China:A Markov model approach

    Shengzhe Lang;Di Wang;Yi Li;Weihua Luo;Gan Xu;Yuwei Wang;Liangru Zhou;P.91-99

    Ethical compliance of drug promotional literature using WHO criteria:Implications for medicines policy and rational use

    Shakil U.Rehman;Mudasir Maqbool;Zulfkar Qadrie;Humaira Ashraf;Mohammad Ali;Shahid Ud Din Wani;P.86-90

    Linked pharmacometrics-pharmacoeconomics model for cost-effectiveness analysis of tacrolimus in liver transplant patients from real-world data

    Aole Zheng;Wen Yao Maka;Xiaoping Shi;Xinyue Zhang;Jiaqi Ni;Yunrong Shen;Zhen Feng;Donghui Lao;Xiao Zhu;Xiaoqiang Xiang;Qingfeng He;P.110-118

    Pharmacoeconomic evaluation for Chinese medicine products:Progress,challenges,and suggestions

    Yunfeng Lai;Dongning Yao;Hao Hu;P.69-76

    Disease burden of pulmonary arterial hypertension attributable to three factors based on the Global Burden of Disease 2021

    Hanxiang Chen;Yaqun Wang;Fanyu Dong;Zixuan Lv;Shengnan Duan;Anqi Wang;Ni Yuan;P.77-85

    Anticipating a regional shift:Preparing the pharmaceutical industry for real-world evidence requirements across East Asia analogous to a Conditional Reimbursement List framework

    Hong Li;Dimitrios Tsourougiannis;David Bin-Chia Wu;Chee-Jen Chang;P.55-59